Cantor Fitzgerald Reiterates Neutral on CVS Health, Maintains $62 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Sarah James has reiterated a Neutral rating on CVS Health, maintaining a price target of $62.
September 10, 2024 | 3:26 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Cantor Fitzgerald has reiterated a Neutral rating for CVS Health, with a maintained price target of $62, indicating no expected significant short-term price movement.
The reiteration of a Neutral rating and maintenance of the $62 price target by Cantor Fitzgerald suggests that the analyst does not foresee significant changes in CVS Health's stock price in the short term. This indicates stability rather than a bullish or bearish outlook.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100